文献速递淋巴瘤

34例原发性甲状腺淋巴瘤患者的临床特征及预后分析

[Clinical characteristics and prognostic analysis of 34 patients with primary thyroid lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

回顾性分析北京同仁医院2010年9月至2023年2月收治的34例新诊断原发性甲状腺淋巴瘤患者的临床与病理资料,采用Kaplan-Meier生存曲线、Log-rank检验及单因素Cox回归分析预后因素。DLBCL患者27例接受化疗,CR 21例、PR 2例、疾病进展6例,5年无进展生存率78.9%、总生存率77.4%;B症状、肿块长径≥10 cm、Ann Arbor Ⅲ~Ⅳ期是影响预后的重要因素(P<0.05)。

要点

  • 34例均以颈部肿物首发,女25例、男9例,DLBCL 29例、MALT淋巴瘤5例。
  • DLBCL患者5年无进展生存率78.9%、总生存率77.4%。
  • B症状、肿块长径≥10 cm、Ann Arbor Ⅲ~Ⅳ期是影响DLBCL患者预后的重要因素(P<0.05)。

核心结论

  • PTL常见于合并桥本甲状腺炎的女性患者,病理类型多为B细胞淋巴瘤,治疗以化疗为主、放疗及手术为辅,预后相对较好。

研究设计与样本

  • 回顾性分析2010年9月至2023年2月北京同仁医院收治的34例新诊断PTL患者的临床和病理资料。
  • 采用Kaplan-Meier生存曲线及Log-rank检验进行生存分析,预后影响因素分析采用单因素Cox回归模型。

主要发现

  • 34例PTL患者均以颈部肿物为首发临床表现,男9例、女25例。
  • 病理诊断为弥漫大B细胞淋巴瘤(DLBCL)29例、黏膜相关淋巴组织(MALT)淋巴瘤5例。
  • DLBCL患者中6例伴有B症状,17例美国东部肿瘤协作组(ECOG)评分≥2分,Ann Arbor分期Ⅰ~Ⅱ期21例、Ⅲ~Ⅳ期8例,肿块长径≥10 cm 4例,14例合并桥本甲状腺炎。
  • DLBCL患者中27例接受化疗,完全缓解(CR)21例、部分缓解(PR)2例、疾病进展6例。
  • DLBCL患者5年无进展生存率78.9%、总生存率77.4%;单因素生存分析显示B症状、肿块长径≥10 cm、Ann Arbor Ⅲ~Ⅳ期是影响患者预后的重要因素(P<0.05)。

关键数值与推荐

  • DLBCL患者中27例接受化疗,CR 21例、PR 2例、疾病进展6例。
  • DLBCL患者5年无进展生存率78.9%、总生存率77.4%。
  • 单因素生存分析显示B症状、肿块长径≥10 cm、Ann Arbor Ⅲ~Ⅳ期是影响患者预后的重要因素(P<0.05)。
  • MALT淋巴瘤患者均为Ⅰ~Ⅱ期、ECOG评分0~1分、无B症状,均进行手术切除,CR 4例、PR 1例。

临床怎么用

  • PTL治疗以化疗为主,放疗及手术为辅。
  • MALT淋巴瘤患者均进行了手术切除。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical characteristics, diagnosis, treatment, and prognosis of primary thyroid lymphoma (PTL) . Methods: A retrospective analysis was conducted on the clinical and pathological data of 34 newly diagnosed PTL patients admitted to Beijing Tongren Hospital from September 2010 to February 2023. The Kaplan-Meier survival curve and Log-rank test were used for survival analysis, and the Cox regression model was applied for univariate analysis of prognostic factors. Results: All 34 PTL patients presented with cervical mass as the initial clinical manifestation. There were 9 males and 25 females. The pathological diagnosis was diffuse large B-cell lymphoma (DLBCL) in 29 patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 5 patients. Among the DLBCL patients, 6 had B symptoms, 17 had an Eastern Cooperative Oncology Group (ECOG) score of ≥2, the Ann Arbor staging was stage Ⅰ-Ⅱ in 21 cases and stage Ⅲ-Ⅳ in 8 cases, the tumor diameter was ≥10 cm in 4 cases, and 14 had concurrent Hashimoto thyroiditis; 27 cases received chemotherapy, with 21 cases achieving complete remission (CR), 2 cases partial remission (PR), and 6 cases of disease progression; the 5-year progression-free survival and overall survival rates were 78.9% and 77.4%, respectively; univariate survival analysis showed that B symptoms, tumor diameter ≥10 cm, and Ann Arbor stage Ⅲ-Ⅳ were significant factors affecting patient prognosis (P<0.05). MALT lymphoma patients were all in stages Ⅰ-Ⅱ, had an ECOG score of 0-1, and were without B symptoms. All patients underwent surgical resection, with 4 cases achieving CR and 1 case PR. Conclusion: PTL is more common in females with concurrent Hashimoto thyroiditis, with the majority of pathological types being B-cell lymphoma. The main treatment is chemotherapy, supplemented by radiotherapy and surgery, and the prognosis is relatively favorable. 目的: 探讨原发性甲状腺淋巴瘤(Primary thyroid lymphoma,PTL)的临床特征、诊断、治疗及预后。 方法: 回顾性分析2010年9月至2023年2月北京同仁医院收治的34例新诊断PTL患者的临床和病理资料,采用Kaplan-Meier生存曲线及Log-rank检验进行生存分析,预后影响因素分析采用单因素Cox回归模型。 结果: 34例PTL患者均以颈部肿物为首发临床表现,男9例,女25例,病理诊断为弥漫大B细胞淋巴瘤(DLBCL)、黏膜相关淋巴组织(MALT)淋巴瘤的患者分别为29例、5例。DLBCL患者中,6例伴有B症状,17例美国东部肿瘤协作组(ECOG)评分≥2分,Ann Arbor分期为Ⅰ~Ⅱ期21例,Ⅲ~Ⅳ期8例,肿块长径≥10 cm 4例,14例合并桥本甲状腺炎;27例接受化疗,完全缓解(CR)21例,部分缓解(PR)2例,疾病进展6例;5年无进展生存率、总生存率分别为78.9%、77.4%;单因素生存分析显示,B症状、肿块长径≥10 cm、Ann Arbor Ⅲ~Ⅳ期是影响患者预后的重要因素(P<0.05)。MALT淋巴瘤患者均为Ⅰ~Ⅱ期、ECOG评分0~1分、无B症状,患者均进行了手术切除,CR 4例,PR 1例。 结论: PTL常见于合并桥本甲状腺炎的女性患者,病理类型多为B细胞淋巴瘤,治疗上以化疗为主,放疗及手术为辅,预后相对较好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang L, Zeng LJ, Ye J, et al. [Clinical characteristics and prognostic analysis of 34 patients with primary thyroid lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 38964925. doi:10.3760/cma.j.cn121090-20240220-00068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。